Kam knew it was important to get screened for colon cancer as soon as she was eligible. With her dad’s side of the family being affected by breast, kidney and prostate cancer, Kam wanted to “get all ...
Colorectal Cancer Awareness Month is observed annually in March and aims to promote screening and early detection, raise awareness, and offer support to those battling the disease. As it has done ...
Q. My doctor prescribed a Cologuard test instead of a colonoscopy. No one mentioned how often Cologuard could result in false positive test results, as mine did. So, a colonoscopy was necessary after ...
It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...
Cologuard Plus™ test raises the performance bar with sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity Cologuard Plus test will minimize ...
The FDA approved Exact Sciences’ Cologuard Plus multitarget stool DNA test to screen adults aged 45 years or older at average risk for colorectal cancer, according to a company press release. Compared ...
Q. My doctor prescribed a Cologuard test instead of a colonoscopy. No one mentioned how often Cologuard could result in false positive test results, as mine did. So, a colonoscopy was necessary after ...
Studies show higher completion rates for mt-sDNA testing and the positive impact of patient navigation in expanding access to underserved and older populations “Exact Sciences’ research at ACG 2025 ...
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...
American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study results versus FIT at ACG High specificity for ...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback